Takeshi Sagara, Taiho Pharmaceutical’s Executive Director, Clinical Development and Medical Affairs, Discovery & Preclinical Research, said, “We believe that future anticancer drug discovery focusing on research and development not only for advanced cancer but also for early-stage recurrent cancer, with an eye on the patient’s journey, will lead to long-term survival and ultimately the overcoming of cancer. Through our collaboration with Guardant Health, we aim to identify and develop biomarker signatures, that arise in early-stage recurrence and contribute to the creation of next-generation treatment methods.”